

Special Issue

New Treatments in Pancreatic Ductal Adenocarcinoma

Message from the Guest Editor

Pancreatic ductal adenocarcinoma (PDAC) continues to increase in incidence; however, survival remains dismal. A large percentage of patients are diagnosed at a late stage when surgery is not technically feasible, leaving few treatment options. A lack of reliable methods of early detection and its therapeutic resistance makes it one of the most highly lethal malignancies. New treatment strategies are being investigated which may ultimately improve the prognosis of pancreatic cancer and potentially convert later-stage patients to having a resectable disease. New treatments for pancreatic cancer are aided by improvements in radiologic imaging, analysis and manipulation of the tumor microenvironment, genomic diagnostics, understanding of pancreatic tumor biology and advances in surgical techniques. In this Special Issue of *Current Oncology*, we invite authors to submit work focusing on new treatments in PDAC. Original articles, as well as review articles focusing on advances in radiologic, medical, surgical, and radiation therapy for pancreatic cancer are welcome. I look forward to hearing from you.

Guest Editor

Dr. Kelly J. Lafaro

Department of Surgery, Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University School of Medicine, Baltimore, MD 21287,
USA

Deadline for manuscript submissions

closed (31 October 2024)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/174231

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)